跳至主要内容
临床试验/NCT04973605
NCT04973605
招募中
1 期

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417as Monotherapy, in Combination With Dexamethasone, Dexamethasone/Carfilzomib, Dexamethasone/Daratumumab, and Dexamethasone/Pomalidomide in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

BeOne Medicines139 个研究点 分布在 12 个国家目标入组 246 人2021年9月16日

概览

阶段
1 期
干预措施
Sonrotoclax
疾病 / 适应症
未指定
发起方
BeOne Medicines
入组人数
246
试验地点
139
主要终点
Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)
状态
招募中
最后更新
10天前

概览

简要总结

The purpose of this study is to assess the safety, tolerability, and efficacy of sonrotoclax as monotherapy and in various combinations in patients with relapsed/refractory (R/R) multiple myeloma (MM) and chromosomal translocation t(11;14).

The study investigates sonrotoclax alone and in combination with dexamethasone and other agents, including carfilzomib, daratumumab, and pomalidomide.

详细描述

Our company, previously known as BeiGene, is now officially BeOne Medicines. Because some of our older studies were sponsored under the name BeiGene, you may see both names used for this study on this website.

注册库
euclinicaltrials.eu
开始日期
2021年9月16日
结束日期
2026年11月1日
最后更新
10天前
研究类型
Interventional
研究设计
Parallel
性别
All

研究者

责任方
Sponsor
主要研究者

BeiGene Clinical Support

Scientific

Beigene Ltd.

入排标准

入选标准

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
  • A confirmed diagnosis of multiple myeloma (must have an M-component in serum and/or urine)
  • Measurable disease defined as:
  • i. M-spike ≥ 500mg/dL, or ii. Urine protein M-spike of ≥ 200 mg/day, or iii. Serum free light chains ≥ 10 mg/dL, and an abnormal κ:λ ratio
  • Participant has documented relapsed or progressive MM on or after any regimen or who are refractory to the most recent line of therapy.
  • i. Relapsed MM is defined as previously treated MM that progresses and requires initiation of salvage therapy but does not meet the criteria for refractory MM.
  • ii. Refractory MM is defined as disease that is nonresponsive (failure to achieve minimal response or development of progressive disease) while on primary or salvage therapy or progresses within 60 days of last therapy.
  • In Part 1 and Part 2 Cohorts 1 and 2 participants should have relapsed or progressive disease and have had ≥ 3 prior lines of therapy including a proteasome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody, and no more available approved therapies.
  • Participants in Part 2 Cohorts 3, 4, and 5 should have relapsed or progressive disease and have had ≥ 1 prior line of therapy. Prior treatment with carfilzomib is allowed but the patient must not be considered carfilzomib refractory by the investigator.
  • Participants in Part 2 Cohorts 6 and 7 should have relapsed or progressive disease and have had 1 to 3 prior lines of therapy and previously treated with a proteasome inhibitor and an IMiD

排除标准

  • Participant has any of the following conditions:
  • Non secretory MM (Serum free light chains \< 10 mg/dL)
  • Solitary plasmacytoma
  • Active plasma cell leukemia (ie, either 20% of peripheral white blood cells or \> 2.0 x 109/L circulating plasma cells by standard differential)
  • Waldenström macroglobulinemia (WM)
  • Amyloidosis.
  • Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome
  • Chronic respiratory disease that requires continuous oxygen
  • Significant cardiovascular disease, including but not limited to:
  • Myocardial infarction ≤ 6 months before screening

研究组 & 干预措施

Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

干预措施: Sonrotoclax

Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

干预措施: Carfilzomib

Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

干预措施: Dexamethasone

Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

干预措施: Dexamethasone

Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

干预措施: Carfilzomib

Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

干预措施: Daratumumab

Part 2 Cohort Expansion

There will be up to 7 expansion cohorts to further evaluate the safety and efficacy of sonrotoclax monotherapy, sonrotoclax plus dexamethasone in combination with dexamethasone plus carfilzomib, and in combination with dexamethasone plus daratumumab

干预措施: Sonrotoclax

Part 1 Dose Escalation

Dose-escalation and de-escalation to determine maximum tolerated dose (MTD) of sonrotoclax plus dexamethasone, sonrotoclax plus dexamethasone plus carfilzomib, sonrotoclax plus dexamethasone plus daratumumab, and sonrotoclax plus dexamethasone plus pomalidomide.

干预措施: Pomalidomide

结局指标

主要结局

Part 1: Number Of Participants Experiencing Dose-limiting Toxicities (DLTs)

时间窗: Up to 28 days

DLTs will be based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 5.0 and will include most grade 3 or higher events, as defined in the protocol.

Part 1 And 2: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), Adverse Events Leading to Discontinuation and Adverse Events of Special Interest (AESIs).

时间窗: Up to 30 days after last dose of study drug

Part 2: Overall response rate (ORR) as Assessed by Investigator

时间窗: Approximately 4 years

Defined as the percentage of participants who achieved a stringent complete response (sCR), complete response (CR), very good partial response (VGPR), or partial response (PR) per International Myeloma Working Group (IMWG) criteria

Part 2: Very Good Partial Response (VGPR) or Better Response Rate as Assessed by Investigator

时间窗: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years]

Defined as the percentage of participants with a documented VGPR or better (including sCR, CR, and VGPR)

Part 2: Complete Response (CR) or Stringent Complete Response (sCR) as Assessed by Investigator

时间窗: Upon study termination (Baseline up to first documentation of disease progression [PD] or death from any cause [approximately 4 years])

defined as the percentage of participants with a documented CR or sCR

次要结局

  • Part 1: Area under the plasma concentration-time curve time 0 to the last measurable concentration (AUClast) After a Single Dose of Sonrotoclax(Cycle 1 (each cycle is up to 28 days))
  • Part 1: Maximum observed plasma concentration (Cmax) After a Single Dose of Sonrotoclax(Cycle 1 (each cycle is up to 28 days))
  • Part 1: Time to reach Cmax (tmax) After a Single Dose of Sonrotoclax(Cycle 1 (each cycle is up to 28 days))
  • Part 1: At Steady-state: AUC last, ss(Cycle 2 (each cycle is up to 28 days))
  • Part 1: At Steady-state: Cmax, ss(Cycle 2 (each cycle is up to 28 days))
  • Part 1: At Steady-state: trough plasma concentration (Ctrough) ss(Cycle 2 (each cycle is up to 28 days))
  • Part 1: At Steady-state: time to reach Cmax (tmax,ss)(Cycle 2 (each cycle is up to 28 days))
  • Part 2: Time to response (TTR) as Assessed by Investigator(Approximately 4 years)
  • Part 2: Duration of response (DOR) as Assessed by Investigator(Approximately 4 years)
  • Part 2: Progression-free survival (PFS) as Assessed by Investigator(Approximately 4 years)
  • Part 2: Overall survival (OS) as Assessed by Investigator(Approximately 4 years)

研究点 (139)

Loading locations...

相似试验